Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody Based Cancer Treatments from Oxford BioTherapeutics

Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, today announced that Boehringer Ingelheim has exercised an option for rights to a fourth novel oncology target from an ongoing discovery collaboration. The target was discovered using OBTs proprietary OGAP® splice variant discovery platform and the option exercise triggers a milestone payment to OBT. Immuno ...